KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Gross Profit: 2009-2024

Historic Gross Profit for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $56.4 million.

  • Nektar Therapeutics' Gross Profit fell 88.61% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.1 million, marking a year-over-year decrease of 67.20%. This contributed to the annual value of $56.4 million for FY2024, which is 6.23% up from last year.
  • Latest data reveals that Nektar Therapeutics reported Gross Profit of $56.4 million as of FY2024, which was up 6.23% from $53.1 million recorded in FY2023.
  • In the past 5 years, Nektar Therapeutics' Gross Profit registered a high of $133.4 million during FY2020, and its lowest value of $53.1 million during FY2023.
  • For the 3-year period, Nektar Therapeutics' Gross Profit averaged around $60.0 million, with its median value being $56.4 million (2024).
  • In the last 5 years, Nektar Therapeutics' Gross Profit skyrocketed by 43.11% in 2020 and then plummeted by 42.29% in 2021.
  • Yearly analysis of 5 years shows Nektar Therapeutics' Gross Profit stood at $133.4 million in 2020, then tumbled by 42.29% to $77.0 million in 2021, then decreased by 8.56% to $70.4 million in 2022, then decreased by 24.63% to $53.1 million in 2023, then increased by 6.23% to $56.4 million in 2024.